Table.

28-day mortality rates by serostatus

	Seronegative		p value	Seropositive		p value
	Monoclonal	Placebo		Monoclonal	Placebo
Casirivimab–imdevimab	396/1633 (24%)	451/1520 (30%)	0·0010	411/2636 (16%)	383/2636 (15%)	0·30*
Casirivimab–imdevimab	24/360 (7%)	24/160 (15%)	0·0047*	26/369 (7%)	18/201 (9%)	0·42*
Tixagevimab–cilgavimab	15/307 (5%)	30/337 (9%)	0·059	22/380 (6%)	27/339 (8%)	0·29

Data are n/N (%); n is event rate; N is population in the study.

^*Calculated by authors of this commentary; not provided in manuscript.